New treatment approaches for advanced or metastatic urothelial carcinoma

Clinical trials presented at the the American Society of Clinical Oncology (ASCO) Genitourinary Cancers (GU) Symposium 2022 have been investigating treatment options for patients with advanced or metastatic UC who are ineligible for or have progressed on platinum-based chemotherapy, in hopes of improving patient prognosis. The LEAP-011 trial explored the addition of the VEGFR inhibitor, lenvatinib, to first-line pembrolizumab for patients ineligible for platinum-based chemotherapy, in hopes of increasing responsiveness to pembrolizumab. The TROPHY-U-01 trial investigated treatment with sacituzumab govitecan for patients with mUC who had progressed on platinum-based chemotherapy and ICIs. The ATLANTIS trial is exploring personalized maintenance treatment options for patients undergoing palliative chemotherapy in biomarker-defined subgroups of patients with advanced UC. 

In this podcast, Yohann Loriot, MD, PhD, Gustave Roussy, Villejuif, France, and the University of Paris-Saclay, Gif-sur-Yvette, France, Petros Grivas, MD, PhD, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA and Simon Crabb, PhD, MBBS, Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK, outline results from these clinical trials. 

The post New treatment approaches for advanced or metastatic urothelial carcinoma appeared first on VJOncology.